<DOC>
	<DOCNO>NCT01709136</DOCNO>
	<brief_summary>Pharmacokinetics Tacrolimus Sirolimus alone combination liver transplant recipient .</brief_summary>
	<brief_title>Pharmacokinetics Sirolimus Tacrolimus Liver Transplant Recipients With Tacrolimus Toxicity</brief_title>
	<detailed_description>Liver transplant patient receive tacrolimus , experience side effect hypertension renal dysfunction , convert sirolimus low-dose tacrolimus , Tacrolimus withdrawal . This study evaluate allograft function serial clinical lab testing , pharmacokinetics sirolimus tacrolimus , glomerular filtration rate ( GFR ) potential side effect sirolimus , marrow suppression hyperlipidemia . Two pharmacokinetic evaluation plan : around third post-transplant month another one 12 month . Expected outcomes , good understand sirolimus pharmacokinetic parameter time pediatric/adult liver recipient early efficacy safety data sirolimus non-nephrotoxic alternative tacrolimus .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Recipients primary liver ( cadaver/liver , whole/segmental ) transplant 5 30 year old . Rejectionfree posttransplant course least 3 month Renal dysfunction ( 15 % decrease ageadjusted calculated creatinine clearance ) Hypertension require antihypertensive mediation . Informed consent . Weight â‰¥15 kg . Rejection infection within 3 month enrollment . Intent continue TAC Active participation ongoing study immunosuppressive agent . Lack informed consent . Pregnant breast feeding HIV positive</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>